UroGen Pharma Announces FDA Filing Acceptance and Priority Review of U.S. New Drug Application (NDA) for UGN-101 | Urogen Pharma Inc.

Potential for UGN 101 to be First Non-Surgical Therapy for the Treatment of Low-Grade Upper Tract Urothelial Cancer (LG UTUC) NEW YORK –(BUSINESS WIRE)–Dec. 19, 2019– UroGen Pharma Ltd. (Nasdaq: URGN) today announced the U.S. Food and Drug Administration ( FDA ) accepted for filing and granted

Read the full article here

Related Articles